PDM-042

• Description :

  PDM-042 is a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. PDM-042 shows potent inhibitory activities for human and rat PDE10A with IC50 values of less than 1 nM and more than 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for the research of schizophrenia[1].

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/pdm-042.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC1=NC=C(C)N2C1=NC(/C=C/C3=NC(N4CCCC4)=CC(N5CCOCC5)=N3)=N2

• Molecular Formula :

  C21H26N8O

• Molecular Weight :

  406.48

• References & Citations :

  [1]Arakawa K, et al. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [ (E) -4- (2- (2- (5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl) vinyl) -6- (pyrrolidin-1-yl) pyrimidin-4-yl) morpholine] in rats: potential for the treatment of schizophrenia. Pharmacol Res Perspect. 2016 Jun 10;4 (4) :e00241.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1404488-48-7]